Eisai lays out US commercial strategy for high-dose Aricept
This article was originally published in Scrip
Eisai is aiming for US sales of at least $600 million by 2012 for its new once-daily 23mg tablet formulation of Aricept (donepezil), which has just been approved by the FDA for the treatment of moderate to severe Alzheimer's disease.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.